Pharma Journalist -

Glioblastoma multiforme (GBM), the most common type of brain cancer, is notoriously difficult to treat. Its tumor cells mutate rapidly, pushing into deep areas of the brain that can be…
Read More...

Gilead Sciences, Inc. announced that the European Commission (EC) has authorized a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir…
Read More...

ANI Pharmaceuticals, Inc. announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Fluoxetine Oral…
Read More...

C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402 million, for its NRF2 Activator programme.  AstraZeneca will develop…
Read More...

Full-Life Technologies, a fully integrated global radiotherapeutics company, announced an agreement to acquire New Jersey-based Focus-X Therapeutics, a company developing targeted…
Read More...

SAE Media Group reports: Agenda and speaker overview released for the 6th Annual 3D Cell Culture Conference, London, UK SAE Media Group is delighted to announce the return of…
Read More...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a…
Read More...

The Global Antibiotic Research and Development Partnership (GARDP) and Mitsubishi Tanabe Pharma Corporation (MTPC) have signed an agreement for GARDP to access over 50,000 compounds…
Read More...

AbbVie announced the European Commission (EC) approved SKYRIZI (risankizumab, 600 mg intravenous induction and 360 mg subcutaneous maintenance therapy) as the first specific…
Read More...

Xeris Biopharma Holdings, Inc. a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of…
Read More...